The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC

Se Hyun Kim, ByoungChul Cho, Hye Jin Choi, Kyung Young Chung, Dae Joon Kim, Moo Suk Park, Se Kyu Kim, Joon Chang, Sang Joon Shin, Joo Hyuk Sohn, Joo Hang Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The prognosis of patients with stage III non-small-cell lung cancer (NSCLC) who achieve a pathological complete response or downstaging following neoadjuvant therapies are better than the prognosis of patients with residual metastatic lymph nodes (LN). However, the prognostic significance of the number of residual metastatic LNs remains unclear. From January 2001 to January 2006, 42 consecutive patients with stage IIIAN2 (22 patients) and IIIB without pleural effusion (20 patients) were treated with neoadjuvant chemotherapy. Thirty-four (81.0%) of the 42 patients were pathologically staged by mediastinoscopy. Neoadjuvant chemotherapy consisted of 3 cycles of platinum-based doublet (21 patients with gemcitabine, 15 with paclitaxel, and 6 with docetaxel). After neoadjuvant chemotherapy, a pathological complete response was achieved in one patient and downstaging was achieved in 24 patients. Pathological LN metastasis was absent in 9 patients (21.4%) and present in 33 patients (78.6%). With a median follow-up of 23 months, the 2-year disease-free survival (DFS) rate of patients without residual LN metastasis was statistically better than that of patients with residual LN metastasis (46% vs. 18% respectively, P = 0.03). Among 33 patients with residual LN metastasis, age (P = 0.01), pathological downstaging (P = 0.098) and the number of residual metastatic LNs (median 14 months in 1-4 LN vs. median 5 months in LN ≥5; P = 0.011) were significant predictors of DFS in univariate analysis. In multivariate analysis, the number of residual metastatic LNs was an independent predictor of DFS among patients with residual LN metastasis, irrespective of pathological downstaging. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy is an independent predictor of DFS in patients with stage III NSCLC.

Original languageEnglish
Pages (from-to)393-400
Number of pages8
JournalLung Cancer
Volume60
Issue number3
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Non-Small Cell Lung Carcinoma
Lymph Nodes
Drug Therapy
Survival
Disease-Free Survival
Neoplasm Metastasis
docetaxel
gemcitabine
Mediastinoscopy
Neoadjuvant Therapy
Pleural Effusion
Paclitaxel
Platinum
Multivariate Analysis
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Kim, Se Hyun ; Cho, ByoungChul ; Choi, Hye Jin ; Chung, Kyung Young ; Kim, Dae Joon ; Park, Moo Suk ; Kim, Se Kyu ; Chang, Joon ; Shin, Sang Joon ; Sohn, Joo Hyuk ; Kim, Joo Hang. / The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. In: Lung Cancer. 2008 ; Vol. 60, No. 3. pp. 393-400.
@article{5bf791e167f04da082d0b65451ad9971,
title = "The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC",
abstract = "The prognosis of patients with stage III non-small-cell lung cancer (NSCLC) who achieve a pathological complete response or downstaging following neoadjuvant therapies are better than the prognosis of patients with residual metastatic lymph nodes (LN). However, the prognostic significance of the number of residual metastatic LNs remains unclear. From January 2001 to January 2006, 42 consecutive patients with stage IIIAN2 (22 patients) and IIIB without pleural effusion (20 patients) were treated with neoadjuvant chemotherapy. Thirty-four (81.0{\%}) of the 42 patients were pathologically staged by mediastinoscopy. Neoadjuvant chemotherapy consisted of 3 cycles of platinum-based doublet (21 patients with gemcitabine, 15 with paclitaxel, and 6 with docetaxel). After neoadjuvant chemotherapy, a pathological complete response was achieved in one patient and downstaging was achieved in 24 patients. Pathological LN metastasis was absent in 9 patients (21.4{\%}) and present in 33 patients (78.6{\%}). With a median follow-up of 23 months, the 2-year disease-free survival (DFS) rate of patients without residual LN metastasis was statistically better than that of patients with residual LN metastasis (46{\%} vs. 18{\%} respectively, P = 0.03). Among 33 patients with residual LN metastasis, age (P = 0.01), pathological downstaging (P = 0.098) and the number of residual metastatic LNs (median 14 months in 1-4 LN vs. median 5 months in LN ≥5; P = 0.011) were significant predictors of DFS in univariate analysis. In multivariate analysis, the number of residual metastatic LNs was an independent predictor of DFS among patients with residual LN metastasis, irrespective of pathological downstaging. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy is an independent predictor of DFS in patients with stage III NSCLC.",
author = "Kim, {Se Hyun} and ByoungChul Cho and Choi, {Hye Jin} and Chung, {Kyung Young} and Kim, {Dae Joon} and Park, {Moo Suk} and Kim, {Se Kyu} and Joon Chang and Shin, {Sang Joon} and Sohn, {Joo Hyuk} and Kim, {Joo Hang}",
year = "2008",
month = "6",
day = "1",
doi = "10.1016/j.lungcan.2007.11.004",
language = "English",
volume = "60",
pages = "393--400",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Kim, SH, Cho, B, Choi, HJ, Chung, KY, Kim, DJ, Park, MS, Kim, SK, Chang, J, Shin, SJ, Sohn, JH & Kim, JH 2008, 'The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC', Lung Cancer, vol. 60, no. 3, pp. 393-400. https://doi.org/10.1016/j.lungcan.2007.11.004

The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. / Kim, Se Hyun; Cho, ByoungChul; Choi, Hye Jin; Chung, Kyung Young; Kim, Dae Joon; Park, Moo Suk; Kim, Se Kyu; Chang, Joon; Shin, Sang Joon; Sohn, Joo Hyuk; Kim, Joo Hang.

In: Lung Cancer, Vol. 60, No. 3, 01.06.2008, p. 393-400.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC

AU - Kim, Se Hyun

AU - Cho, ByoungChul

AU - Choi, Hye Jin

AU - Chung, Kyung Young

AU - Kim, Dae Joon

AU - Park, Moo Suk

AU - Kim, Se Kyu

AU - Chang, Joon

AU - Shin, Sang Joon

AU - Sohn, Joo Hyuk

AU - Kim, Joo Hang

PY - 2008/6/1

Y1 - 2008/6/1

N2 - The prognosis of patients with stage III non-small-cell lung cancer (NSCLC) who achieve a pathological complete response or downstaging following neoadjuvant therapies are better than the prognosis of patients with residual metastatic lymph nodes (LN). However, the prognostic significance of the number of residual metastatic LNs remains unclear. From January 2001 to January 2006, 42 consecutive patients with stage IIIAN2 (22 patients) and IIIB without pleural effusion (20 patients) were treated with neoadjuvant chemotherapy. Thirty-four (81.0%) of the 42 patients were pathologically staged by mediastinoscopy. Neoadjuvant chemotherapy consisted of 3 cycles of platinum-based doublet (21 patients with gemcitabine, 15 with paclitaxel, and 6 with docetaxel). After neoadjuvant chemotherapy, a pathological complete response was achieved in one patient and downstaging was achieved in 24 patients. Pathological LN metastasis was absent in 9 patients (21.4%) and present in 33 patients (78.6%). With a median follow-up of 23 months, the 2-year disease-free survival (DFS) rate of patients without residual LN metastasis was statistically better than that of patients with residual LN metastasis (46% vs. 18% respectively, P = 0.03). Among 33 patients with residual LN metastasis, age (P = 0.01), pathological downstaging (P = 0.098) and the number of residual metastatic LNs (median 14 months in 1-4 LN vs. median 5 months in LN ≥5; P = 0.011) were significant predictors of DFS in univariate analysis. In multivariate analysis, the number of residual metastatic LNs was an independent predictor of DFS among patients with residual LN metastasis, irrespective of pathological downstaging. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy is an independent predictor of DFS in patients with stage III NSCLC.

AB - The prognosis of patients with stage III non-small-cell lung cancer (NSCLC) who achieve a pathological complete response or downstaging following neoadjuvant therapies are better than the prognosis of patients with residual metastatic lymph nodes (LN). However, the prognostic significance of the number of residual metastatic LNs remains unclear. From January 2001 to January 2006, 42 consecutive patients with stage IIIAN2 (22 patients) and IIIB without pleural effusion (20 patients) were treated with neoadjuvant chemotherapy. Thirty-four (81.0%) of the 42 patients were pathologically staged by mediastinoscopy. Neoadjuvant chemotherapy consisted of 3 cycles of platinum-based doublet (21 patients with gemcitabine, 15 with paclitaxel, and 6 with docetaxel). After neoadjuvant chemotherapy, a pathological complete response was achieved in one patient and downstaging was achieved in 24 patients. Pathological LN metastasis was absent in 9 patients (21.4%) and present in 33 patients (78.6%). With a median follow-up of 23 months, the 2-year disease-free survival (DFS) rate of patients without residual LN metastasis was statistically better than that of patients with residual LN metastasis (46% vs. 18% respectively, P = 0.03). Among 33 patients with residual LN metastasis, age (P = 0.01), pathological downstaging (P = 0.098) and the number of residual metastatic LNs (median 14 months in 1-4 LN vs. median 5 months in LN ≥5; P = 0.011) were significant predictors of DFS in univariate analysis. In multivariate analysis, the number of residual metastatic LNs was an independent predictor of DFS among patients with residual LN metastasis, irrespective of pathological downstaging. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy is an independent predictor of DFS in patients with stage III NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=44249100649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44249100649&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.11.004

DO - 10.1016/j.lungcan.2007.11.004

M3 - Article

C2 - 18155802

AN - SCOPUS:44249100649

VL - 60

SP - 393

EP - 400

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -